Abstract
BackgroundPapillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. It has a poorer prognosis than clear cell RCC (ccRCC) with a lack of standard treatments.Case presentationWe report the case of a 51 year old man with a metastatic pRCC (hepatic dome and left colonic peritoneal carcinomatosis) progressive after sunitinib, with a MET amplification. The patient was enrolled in the UNICANCER-sponsored AcSé crizotinib trial (NCT02034981), designed to give an access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug. With 2nd line crizotinib (250 mg twice/day), the patient had a very good tolerance, a partial response in the target lesions using RECIST 1.1, and a 19 months’ clinical efficacy.ConclusionsIn metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.
Highlights
Papillary renal cell carcinoma is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma (RCC)
We present the case of a man with a metastatic Papillary renal cell carcinoma (pRCC) (mpRCC), progressive after sunitinib, for which the diagnosis of Mesenchymal epithelial transition protooncogene (MET) amplification led to use crizotinib in 2nd line with a 19 months’ efficacy, and a very good tolerance (ECOG 0, 100% professional activity)
Diamond et al described a pRCC patient with an activating MET gene mutation, pretreated by sunitinib and everolimus, with a long response to a tyrosine kinase inhibitor (TKI: PF-04217903) [10]. This situation is rare in routine clinical practice, as MET copy number amplifications are more frequent in pRCC (81% of type 1 in the series of Albiges et al.) than intracellular domain MET mutations (21%) [11]; the development of this TKI has stopped
Summary
Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. We present the case of a patient with a MET-amplified mpRCC successfully treated during 19 months with the MET-inhibitor crizotinib within the French AcSé- crizotinib program [6].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
